Introduction
Traditionally, allogeneic hematopoietic stem cell transplantation has relied on intensive and toxic cytoreductive conditioning therapy, thus requiring 3-5 weeks of hospitalization for the treatment and management of various complications. The cost of this procedure is beyond the reach of the majority of patients in the developing world; 1 furthermore, in Mexico, there are few hospitals with the traditional bone marrow transplantation unit designed to perform myeloablative allogeneic stem cell transplantation (ASCT). ASCT using reduced intensity conditioning or non-myeloablative stem cell transplantation (NST) has been developed to induce host versus graft transplantation tolerance with fast engraftment of donor stem cells and subsequently graft-versus-host and graft-versus-tumor effect. 2, 3 NST can be used in elderly individuals and other high-risk patients otherwise excluded from conventional allografting; furthermore, as it is more affordable, NST has become the method of choice in locations with limited resources. 4 Several methods of conducting NST have been described worldwide; we have used the 'Mexican' method for the last 8 years. 5 NST can be accomplished partially or totally on an outpatient basis because it leads to less toxicity; therefore neutropenia and the risk of infection are reduced. 6 In a country like Mexico, where a significant percentage of the population does not have access to public social security or to sufficient funds to cover the cost of transplantation, the concept of employing cheaper effective procedures is very important to reach the goal of curing as many patients as possible.
One hundred and thirty-two patients were allografted using the 'Mexican' method. All of the procedures were started on outpatients, but some individuals had to be admitted to the hospital. In this article, we describe our experience and analyze certain characteristics of patients who were allografted totally as outpatients and compare them with those who were not, to identify variables, which could enable us to predict the feasibility of completing the allograft totally on an outpatient basis.
Materials and methods

Patients and donors
The study accrues all the patients given an allogeneic HSC transplant consecutively at the Hospital Universitario 'Dr Jose E Gonzalez' (Monterrey, Mexico) and at the Centro de Hematologı´a y Medicina Interna de Puebla (Puebla, Me´xico) from 1999 to 2005. In all instances, the donor was a human leukocyte antigen (HLA)-compatible (6/6) sibling. Institutional Review Board approval and written consent for an outpatient transplant was obtained from all the individuals. The hematology service in Monterrey is very similar to the Puebla service, both having a complete blood bank, laboratory and outpatient clinical facilities, including a 7-day a week clinic. Given the limited availability of funds to carry out conventional transplants and the simplification of the procedure utilizing non-myeloablative conditioning, this outpatient procedure is standard practice in our field. In all cases, patients were free to choose whether to receive the transplant as inpatients or outpatients; moreover, during the transplant, they could elect to be admitted to the hospital. Individuals with malignant and nonmalignant hematological conditions, as well as solid tumors, were included; all were required to have a Karnofsky score of at least 70%, serum creatinine levels of less than 2 mg/dl, a preserved oral route, a residence close to the hospital in a clean facility with telephone access and the permanent company of a caregiver (relative or friend) throughout the treatment. Hemoglobin (Hb) and platelet values were not used as selection criteria.
Other criteria used to determine the application of the ambulatory procedure were the availability of an area designated for the exclusive use of the patient within the residence, the appropriate educational level of both the patient and the caregiver, and both parties having complete instructions relating to the attention and controls to be observed during the procedure. This required deep involvement among the patient, his family and the transplant team.
Hematopoietic stem cell mobilization and apheresis G-CSF (10 mg/kg/day) was delivered to the sibling donors on day À5 to þ 2. The apheresis procedures were performed on days 0, þ 1 and þ 2, according to cell counts with a Haemonetics V-50 PLUS machine (Haemonetics Corporation, Braintree, MA, USA) or a Baxter C-3000 PLUS machine (Baxter Healthcare, Deerfield, IL, USA), using the Spin-Nebraska protocol. 7 About 5000-7000 ml of blood/m 2 were processed in each of the apheresis procedures to obtain a minimum of 5 Â 10 8 mononuclear cells (MNCs) and/or 2-6 Â 10 6 viable CD34 cells/kg of the recipient. Enumeration of the total white blood, MNC and CD34-positive cells was carried out by flow cytometry in an EPICS Elite ESP apparatus (Coulter Electronics, Hialeah, FL, USA), using the anti-CD34 monoclonal antibody HPCA-2 (Becton Dickinson, San Jose´CA, USA). 8, 9 No purging procedures were performed.
Conditioning and grafting
The 'Mexican' NST conditioning regimen was employed, 5, [10] [11] [12] which is a simplification of the low-intensity conditioning regimens used in Houston by Giralt et al. 13 and in Jerusalem by Slavin et al. 7 Oral busulfan, 4 mg/kg was delivered on days À6 and À5; intravenous (i.v.) cyclophosphamide, 350 mg/m 2 on days À4, À3 and À2; i.v. fludarabine, 30 mg/m 2 on days À4, À3 and À2; oral cyclosporin A (CyA) 5 mg/kg was started on day À1 and i.v. methotrexate (5 mg/m 2 ) was delivered on days þ 1, þ 3, þ 5 and þ 11. Conditioning was not given in the hospital; patients received chemotherapy at the outpatient clinic and were discharged after the procedure. Between the start of the conditioning regimen and reaching a granulocyte count above 0.5 Â 10 9 /l, the patients were examined in the outpatient clinic on a daily basis. All of them were instructed to report the presence of fever (4381C), oral intolerance, diarrhea, jaundice, bleeding or any other abnormality. Hospital beds were kept available for those patients needing admission. During outpatient surveillance, patients received only oral drugs: Ondansetron (1 mg p.o. every 12 h for 2 days after i.v. chemotherapy), ciprofloxacin (500 mg b.i.d.), fluconazole (100 mg b.i.d.) and acyclovir (400 mg b.i.d.). The oral route was switched to i.v. only if patients were admitted to the hospital. The products of PBSC apheresis were reinfused as an outpatient procedure on days 0-2 according to the CD34 cell yield (vide supra). Oral CyA was continued through day 180 with adjustments according to whole blood CyA levels; it was then tapered over 30-60 days. If GVHD data were present, the CyA tapering was carried out over longer periods. Red blood cell transfusions were given if the patient had a Hb level below 8.0 g/dl, and apheresis platelets were given if the platelet count (Plt) fell below 20 Â 10 9 /l or if there were signs of bleeding.
Patient surveillance was carried out by physicians on the transplantation teams. All patients had a caregiver at home (a relative or friend) who took care of food preparation, assisted in personal hygiene, controlled the scheduling and dosage of the prescribed medicine (only oral) and was alert to any complication that required medical attention. In the case of patients from the Centro de Hematologı´a y Medicina Interna de Puebla, the expenses of transplantation were fully covered by the patients themselves. For the rest of the patients, expenses were covered by government funds drawn from the social security system. Transportation expenses were covered by the patients themselves.
Molecular biology studies
In cases of a sex mismatch, a fluorescent in situ hybridization technique was carried out to demonstrate the X and Y chromosomes, whereas restriction fragment length polymorphism studies in the peripheral blood lymphocytes were used in the other cases.
14,15 These studies were carried out at diagnosis, 15, 30 and 60 days following the allograft, and every 2-6 months afterwards. 15 
Statistical analysis
Both univariate and multivariate analysis was used. The Kaplan-Meier method was employed to estimate the cumulative incidence for overall survival and compared with the log rank test.
Results
Patients
The study involved 132 patients, 82 men and 50 women with a median age of 36 years (range 8-61). Both hematological and non-hematological malignancies were included, as well as nonmalignant hematological diseases. Table 1 shows the distribution of diseases that led to the allograft. Karnofsky score values in all patients were 70% or greater.
Conditioning
Oral busulphan and i.v. cyclophosphamide and fludarabine were delivered on an outpatient basis to all patients according to the conditioning regimen described previously 5, 6, [8] [9] [10] [11] [12] as well as antiemetic and prophylactic antibiotics. All of the 132 individuals started the allografting procedure on an outpatient basis, of whom 103 (78%) completed the procedure without being admitted to the hospital (group A). No infections were suspected or detected in this group. Only 29 (22%) patients were admitted to the hospital because of fever, mucositis, acute graft-versus-host disease (GVHD) or some other complication, of whom 17 were given i.v. broad spectrum antibiotics (group B). There was only one death before engraftment in group B. This patient had myelodysplastic syndrome and was admitted at day þ 3 with a fever that lasted 4 h. She received antibiotics and exhibited a transitory improvement on day þ 5, but she eventually deteriorated and died on day þ 11 as a result of multiorgan failure. There was no infection site detected during her admission evaluation. The CBC showed pancytopenia and fewer than 0.5 Â 10 9 /l neutrophils while the biochemical profile was normal, as were the heart and lung functions.
Analysis of variables
Several variables were analyzed in the two groups when the allografting procedure began: diagnosis, Hb levels, white blood cell count (WBC), Plt, Karnofsky score and serum creatinine levels ( Table 2) .
Group A. In this group of 103 patients, 91 were allografted as a result of malignancy while 12 had a nonmalignant condition. Packed red cell transfusions were used ranging from 0 to 2 with a median of 0; likewise, the apheresis platelet transfusion ranged from 0 to 2 with a median of 0.
Group B. In this group of 29 patients, 23 were allografted as a result of a malignancy while 6 had a nonmalignant condition. Ten patients were admitted to the hospital because of fever, eight as a result of severe mucositis, nine with fever and mucositis and two because of acute GVHD. The median number of days of hospital stay was 11 (range 4-24 days). The packed red cell transfusions ranged from 0 to 2 with a median of 0, while the apherisis platelet transfusions ranged from 1 to 2 with a median of 1.
Differences
When the allograft procedure was initiated, Hb values were higher for patients in group A (outpatient allografting) than for those in group B (P40.05). WBC values were lower for patients in group A than for those in group B (P40.05), while Plt values were higher for patients in group A than for those in group B (P ¼ 0.037). By the same token, creatinine levels were lower in group A (P40.05), and Karnofsky scores higher in group A (P40.05). We found that 85.7% of a subset of 42 patients with totally normal values of Hb, WBC, Plt, creatinine and high Karnofsky scores could be allografted outside the hospital, whereas only 67% of a subset of patients with abnormal values for all these variables could complete the procedure totally as outpatients. Table 2 summarizes these data. According to the Kaplan-Meier method (Figure 1 ), the overall survival of patients in group A was also better than that of patients Table 1 Distribution of the diseases that led to allograft using the 'Mexican' non-myeloablative conditioning regimen Figure 1 Overall survival of the patients allografted, using the 'Mexican' non-ablative conditioning regimen, who could be allografted totally as outpatients (group A) and those who had to be admitted to the hospital (group B). The differences are not statistically significant.
in group B; however, the difference was not statistically significant. The same is true for patients with malignant and nonmalignant diseases (Figures 2 and 3) . A quality of life test was applied with the COOP/WONCA tests, in which the outpatient group referred to a better quality of life in terms of health status and daily work activity, but no statistical difference was found when compared with the inpatient group.
Discussion
Currently, allogeneic and autologous HSC transplantations are the treatment of choice for several malignant and nonmalignant blood disorders. The development of effective control of GVHD, antiviral and antifungal drugs and the shift to outpatient care have resulted in an important reduction in the cost of transplantation in the developed world. However, the cost of conventional transplantation using a special bone marrow transplantation hospital unit and a standard myeloablative conditioning regimen is still unaffordable for the majority of patients living in the developing world. 16 Me´xico is a country with 110 million inhabitants where more than 50% have a low income; as a result, very few traditional ablative bone marrow transplantation units for inpatient treatment are available.
There is little information about the outpatient conduction of ASCT. Most papers dealing with this topic refer to autologous transplantation. 1, [17] [18] [19] Svahn et al. 20 studied the long-term follow-up of patients treated at home during the pancytopenic phase after myeloablative allogeneic HSC transplantation. In this study, the conditioning regimen was given in the hospital, and after graft infusion the patient could go home where an experienced nurse provided daily care. Researchers found several advantages for the patient in addition to the reduced risk of acute GVHD and toxic related mortality; fewer days on parenteral nutrition, earlier discharge to the outpatient clinic, increased comfort level of staying with the family and lower cost of home care compared to hospital care.
In an effort to deliver effective treatments to a larger number of patients, we have been studying changes in the therapeutic approaches of hematological diseases that could result in both simplification and cost reduction in the procedures. 5 In a pilot study conducted during 2000, we showed that allogeneic HSC transplantation could be performed safely on an outpatient basis. In contrast to the study of Svahn et al., these transplants were performed totally on an outpatient basis using a low-intensity preparative regimen. 6 Since then, we have been allografting individuals almost exclusively on an outpatient basis. We have found that some of these patients have to be admitted to the hospital, mainly for fever in the presence of neutropenia, mucositis or grade III and IV GVHD. In the present study, 103 out of 132 patients could be allografted in an outpatient setting without admittance to the hospital; this group of patients had normal or nearly normal CBC, creatinine and high Karnofsky scores. Interestingly, age by itself was not found to be a critical factor in predicting the outpatient performance of the allograft, since the median age for patients allografted outside the hospital was 34 years and for those eventually admitted was 32 years. The Plt was somewhat predictive in the multivariate analysis (Po0.05), but the median Plt was normal in both groups. Owing to the small numbers in the inpatient group, we were unable to show statistically significant differences between both groups. Of the group of 29 patients who had to be admitted to the hospital, 10 were admitted for fever, 17 for mucositis (nine had both fever and mucositis) and only two as a result of GVHD. These individuals stayed at the hospital for a median of 11 days with a range of 4-24 days. Related to this, Subiraé t al. 4 in Spain were able to show that the length of inpatient days could be reduced from 29 to 9 in a group of 41 patients allografted if reduced-intensity conditioning methods were used. Recently, Leger et al. 19 have published their experience with 60 patients with follicular lymphoma and autologous transplantation; only 6 were well enough to be treated solely in the outpatient setting and 90% required at least one inpatient admission (median 7 days).
The outpatient allografting program cannot be offered indiscriminately to all patients requiring a SCT; it is optimal for those asymptomatic, fully active, able to stay in their homes with trained caregivers (relatives or friends) or in nearby hotels and those with an adequate educational level. Fundamental to the success of the outpatient approach is the availability of the 7 day-a-week clinic where medications and transfusions can be rapidly and efficiently provided for cytopenias, if required. 6 In conclusion, we have shown that allografting on a totally outpatient basis is safe, effective and feasible for patients with appropriate physical condition using the 'Mexican' approach of ASCT.
